← Eichor
Study identifier: NCT05988515 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

AI-Assisted Treatment for Residual Speech Sound Disorders

Condition: Speech Sound Disorder  ·  Sponsor: Syracuse University

PhaseNA
Planned participants26
Who can joinAll sexes, 9 Years to 17 Years
Healthy volunteersYes

About this study

The goal of this randomized-controlled trial is to determine how artificial intelligence-assisted home practice may enhance speech learning of the "r" sound in school-age children with residual speech sound disorders. All child participants will receive 1 speech lesson per week, via telepractice, for 5 weeks with a human speech-language clinician. Some participants will receive 3 speech sessions per week with an Artificial Intelligence (AI)-clinician during the same 5 weeks as the human clinician sessions (CONCURRENT treatment order group), whereas others will receive 3 speech sessions per week with an AI-clinician after the human clinician sessions end (SEQUENTIAL treatment order group.

This description comes directly from the study's public registry record.

Talk to the study team

Jonathan Preston, PhD  ·  315-443-1351  ·  jopresto@syr.edu

Nina Benway, PhD  ·  nrbenway@syr.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Syracuse UniversitySyracuse, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05988515